Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron watches several high-value NASH related deals

Microbiome company Immuron (ASX:IMC) is witnessing a series of high-value licensing merger & acquisition (LM&A) deals related to NASH (non-alcoholic steatohepatitis) assets.
Immuron watches several high-value NASH related deals
Immuron is currently running clinical trials in fatty-liver diseases

Gilead (NASDAQ:GILD) has paid a $100 million milestone payment to Phenex following its licensing deal of Phenex’s Farnesoid X Receptor NASH Phase I clinical program in 2015.

This latest NASH milestone payment re-affirms Immuron’s belief that the LM&A market surrounding NASH technologies will remain extremely attractive, and active, for the foreseeable future.

The company’s long-term strategy is to secure a partner at the right time for its fatty-liver program.

Immuron is currently running three Phase II clinical trials in fatty-liver diseases with its lead product candidate IMM-124E including NASH, ASH (Alcoholic Steatohepatitis) and Pediatric NASH.

Both the ASH and Pediatric NASH trials are funded by the U.S. National Institutes of Health (NIH).

IMM-124E works upstream, and on several pathways, to reduce liver inflammation and is thus a completely unique treatment option compared to other leading investigational agents.

IMM-124E has the potential to be one of the backbone therapies for NASH patients.

As the worldwide prevalence of obesity and diabetes reaches epidemic proportions, the unmet need for treatments continues to grow.

In 2015, Pharmaxis’ NASH assets (Phase 1) were licensed by Boehringer ingelheim for a total potential deal value of US$600 million.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017

Related Articles

pills
July 26 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
mountains
August 22 2018
So far, the hit rate is a five out of 12 success rate for its investments

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use